AVS POST

Category: Covid-19

  • Union Health Minister Mansukh Mandaviya review status of essential medicines and drugs with Pharma Companies in view of spike in COVID19 cases in some countries

    Union Health Minister Mansukh Mandaviya review status of essential medicines and drugs with Pharma Companies in view of spike in COVID19 cases in some countries

    Union Minister of Health & Family Welfare and Chemicals & Fertilizers, Dr. Mansukh Mandaviya reviewed the status, adequacy of COVID management drugs and production capacities with representatives of pharma companies through a VC, here today, so that India is equipped to effectively handle any situation. This review meeting was taken in view of the spike in COVID19 cases in some countries worldwide.

    Through a presentation, the Union Minister was briefed regarding the evolving global scenario. Dr Mansukh Mandaviya appreciated and congratulated the pharma companies for their invaluable contribution during the COVID pandemic in the country. “India’s pharmaceutical industry is robust, resilient and responsive. It is due to their strength that we could not only meet our down demand during the pandemic, but also be in a position to supply medicines to 150 countries.” This was achieved without any fall in quality and no hike in the price of the medicines, he stressed.

    The pharma companies were asked to keep a close watch on the global supply chain scenario. They were also asked to closely monitor production and availability of APIs as well as formulations of essential medicines for COVID management. They were asked to ensure adequate stocks and availability of all drugs including COVID drugs in the supply chain up to the retail level.

    The pharma companies hailed the timely review meeting chaired by the Union Minister and assured their continued support. They expressed confidence that they will be able to manage the supply chain of COVID drugs.

    Shri Rajesh Bhushan, Union Health Secretary, Ms. S Aparna, Secretary (Pharma), Shri Kamlesh Pant, Chairman, NPPA, Dr V G Somani, DCGI, and representatives from pharmaceutical companies were present during the review meeting.

  • India’s Cumulative COVID-19 Vaccination Coverage exceeds 178.55 Cr

    India’s Cumulative COVID-19 Vaccination Coverage exceeds 178.55 Cr

    New Delhi: With the administration of more than 24.62lakh Doses (24,62,562) vaccine doses in the last 24 hours, India’s COVID-19 vaccination coverage has exceeded 178.55Cr (1,78,55,66,940) as per provisional reports till 7 am today. (Data Till 3rd march 2022)

    This has been achieved through 2,06,52,074sessions. The break-up of the cumulative figure as per the provisional report till 7 am today include:

    Cumulative Vaccine Dose Coverage
    HCWs 1st Dose 1,04,01,981
    2nd Dose 99,73,554
    Precaution Dose 42,29,049
    FLWs 1st Dose 1,84,10,265
    2nd Dose 1,74,55,444
    Precaution Dose 63,53,448
    Age Group 15-18 years 1st Dose 5,52,63,296
    2nd Dose 3,01,57,910
    Age Group 18-44 years 1st Dose 55,23,68,002
    2nd Dose 44,83,30,464
    Age Group 45-59 years 1st Dose 20,23,64,644
    2nd Dose 18,10,79,986
    Over 60 years 1st Dose 12,64,84,390
    2nd Dose 11,27,69,772
    Precaution Dose 99,24,735
    Precaution Dose 2,05,07,232
    Total 1,78,55,66,940

     

    11,651patients have recovered in the last 24 hours and the cumulative tally of recovered patients (since the beginning of the pandemic) is now at 4,23,78,721.

    Consequently, India’s recovery rate stands at 98.65%.

     

    5,921new cases were reported in the last 24 hours.

    India’s Active Caseload is presently at 63,878. Active cases constitute 0.15% of the country’s total Positive Cases.

    The testing capacity across the country continues to be expanded. The last 24 hours saw a total of 9,40,905tests being conducted. India has so far conducted over 77.19 Cr (77,19,14,261) cumulative tests.

    While testing capacity has been enhanced across the country, Weekly Positivity Rate in the country currently stands at 0.84% and the Daily Positivity rate is reported to be 0.63%.